Page last updated: 2024-08-25

3-deazaneplanocin and capecitabine

3-deazaneplanocin has been researched along with capecitabine in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cruz-Monserrate, Z; Govindarajan, R; Griffin, J; Hung, SW; Mody, HR; Pathak, RK	1

Other Studies

1 other study(ies) available for 3-deazaneplanocin and capecitabine

Article	Year
miR-202 Diminishes TGFβ Receptors and Attenuates TGFβ1-Induced EMT in Pancreatic Cancer. Molecular cancer research : MCR, 2017, Volume: 15, Issue:8 Topics: Adenosine; Animals; Capecitabine; Cell Line, Tumor; Deoxycytidine; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lentivirus; Mice; MicroRNAs; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays	2017

Article

Year

miR-202 Diminishes TGFβ Receptors and Attenuates TGFβ1-Induced EMT in Pancreatic Cancer.

Molecular cancer research : MCR, 2017, Volume: 15, Issue:8

Topics: Adenosine; Animals; Capecitabine; Cell Line, Tumor; Deoxycytidine; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lentivirus; Mice; MicroRNAs; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays

2017